Praised for preventing hundreds of thousands of deaths and allowing a return to a more normal life, Covid vaccines will also substantially benefit some pharmaceutical companies.
In June, analysts estimated the global vaccine market could be worth $ 70 billion (£ 50 billion) this year, but the figure could be even higher as the Delta variant of the coronavirus spreads and the scientists wonder if people will need booster shots.
Moderna, who has received funding from the US government to develop his vaccine, will reveal how much he earned in the second quarter on Thursday. He projected $ 19.2 billion in revenue for 2021 from the vaccine in May, but that estimate could rise this week.
With his fellow American Pfizer, he will carve out the lion’s share of the global benefits of the Covid vaccine. The companies charge more than $ 30 per person for the two required injections in Europe and the United States, while the largest British drug maker, AstraZeneca, and the United States Johnson & Johnson (J&J) have pledged to provide the their nonprofits until the pandemic ends.
New York-based Pfizer made $ 11.3 billion in the first half of this year thanks to the Covid coup it developed with Germany’s BioNTech, and last week raised its sales forecast for 2021 to 33 , 5 billion dollars against 26 billion dollars. Both companies have tweaked their mRNA vaccine to target the Delta variant and will begin testing it in humans this month.
Pfizer’s total sales jumped 86% in the second quarter, but only rose 10% when sales of Covid vaccines were phased out. Morningstar analyst Damien Conover said sales growth would slow over the next 12 months as demand for vaccines shifted to emerging markets where prices were lower: compromise. There is upside potential if a greater demand for boosters emerges or if new vaccines are developed for variants. “
The vaccine also transformed the fortunes of Moderna, a Massachusetts biotech company founded in 2010, which made its first quarterly profit from $ 1.7 billion in revenue in the first three months of the year.
The business success of the two companies contrasts with the non-profit path taken by AstraZeneca and J&J, which sell their jabs at a much lower price (AstraZeneca charges between $ 4.30 and $ 10 for two doses while J&J billed the government US $ 10 per dose for its single injection vaccine).
Still, the jab developed by the University of Oxford and AstraZeneca grossed the pharmaceutical company $ 1.2 billion in the first half of the year.
One of the first vaccines to be approved globally, it is now shipped worldwide – sales were almost evenly split between Europe and emerging economies in the first half of the year.
Despite the production of the world’s leading vaccines, the United States exported few vaccines. While there is no formal export ban, Washington has used a war power known as the Defense Production Act to force companies to fulfill their orders before others.
However, in June, US President Joe Biden announced that the United States would donate half a billion Pfizer vaccines to 92 low- and lower-middle-income countries and the African Union, “to restart the global fight. against the pandemic ”. As part of this pledge, nearly 5.7 million doses of Pfizer are expected to arrive in South Africa this week, and 4 million to Nigeria.
Only 14.4% of the world’s population is fully immunized; 28% received at least one dose of a vaccine, with 4.07 billion doses administered worldwide. Only 1.1% of people in low-income countries received at least one dose.
AstraZeneca has suffered many setbacks, including supply issues that led to a legal battle with the European Commission, and a link to rare blood clots (although a new study last week indicated that its vaccine safety profile is similar to that of the Pfizer jab). It postponed filing for regulatory approval in the United States until the second half of the year because, he said, it took a long time to put together the large datasets required by the US regulator.
The EU will no longer order vaccines from AstraZeneca, and disillusionment has set in. It is known that it is considering “all options” for the vaccine sector, including a potential sale by the end of this year.